Does Astrazhenka vaccine work against the new Omicron strain?

Astrazenka hopes that the Covid-19 antibody cocktail will remain effective against the new Corona strain, which is expanding in South Africa. The company is also examining whether this strain is also resistant to the Astrazenka vaccine.

The company said in a statement: “We are investigating B.1.1.529, like any new emerging strain, to learn more about it and its effect on the vaccine. We are also conducting research in Botswana and Swatini to collect data.”

Astrazenka is testing its antibody composition AZD7442 against this new strain and hopes that AZD7442 will retain its effectiveness because it contains two strong antibodies with different and complementary anti-virus activities.

The World Health Organization on Friday classified the B.1.1.529 strain of coronavirus as a worrying strain and named it (Omicron). In the classification of coronaviruses, a type that is associated with increased transmission, infection, or immunity to vaccines falls into the category of worrying strains.

“This species (B.1.1.529) has a large number of mutations, some of which are worrisome,” said the World Health Organization. “Preliminary evidence suggests an increased risk of re-infection with this strain compared to other worrying strains.”

The number of cases of amicron appears to be increasing in almost all South African provinces, the agency said.

The WHO has called on countries to step up monitoring and sequencing efforts to better understand circulating SARS-COO-2 variants, and called on governments to send complete genome sequences and related metadata to a publicly available database.

The new corona mutation was named ‘omicron’ and was classified as a ‘worrying strain’

Countries have been asked to report the first cases or clusters related to this strain. Field research and laboratory analysis should also be conducted, if capacity is available, in coordination with the international community.

The organization called on the public to take steps to reduce the risk of Covid-19 and to follow all protocols, including vaccination.

Type B.1.1.529 was first identified in South Africa on November 24, and the World Health Organization stated that the epidemiological situation in the region was marked by three peaks, the last of which was mainly the delta type.

Regarding the situation in South Africa, the World Health Organization said: “In recent weeks, at the same time as the identification of type B.1.1.529, the incidence has increased sharply and the first confirmed infection was B.1.1.529. Collected November 2021.

“Scientists have found no evidence that this is a serious disease,” South African Health Minister Joe Fahla told a news conference.

He also stressed that so far no scientific evidence has been reported of an aggressive increase in B.1.1.529.

“It’s too early to say how the new Covid-19 will behave,” Fahla said.

“This new species could pose such a threat to vaccines that the world is facing a ‘completely new epidemic,'” a Coved expert said.

“This is a serious threat because its proliferation of 32 mutations indicates that it has a greater capacity to evade vaccine immunity,” said Dr. David Nabarro, the World Health Organization’s special envoy.

He added: “It looks like the virus will have a greater capacity to escape the body’s defenses, which we have all received as a result of vaccinations, and this is worrying because it shows a relapse and a resumption of a new epidemic.”

Several countries have imposed travel restrictions due to the emergence of the new route; Britain, South Africa and five other countries (Botswana, Lesotho, Swatini, Zimbabwe and Namibia) are on the red list to prevent the introduction of a new species of Coyote.

The Astrazeneca vaccine provides greater immunity